Insider Selling: Integer Holdings Co. (NYSE:ITGR) Director Sells 14,739 Shares of Stock

Integer Holdings Co. (NYSE:ITGR) Director Donald J. Spence sold 14,739 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director now owns 18,781 shares of the company’s stock, valued at $2,260,856.78. This trade represents a 43.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Integer Trading Up 0.3%

NYSE ITGR opened at $121.25 on Friday. Integer Holdings Co. has a twelve month low of $104.93 and a twelve month high of $146.36. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of 36.09, a PEG ratio of 1.72 and a beta of 0.98. The firm’s 50 day moving average price is $118.81 and its two-hundred day moving average price is $128.08.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. Integer had a net margin of 6.92% and a return on equity of 11.65%. The firm had revenue of $437.39 million for the quarter, compared to analysts’ expectations of $428.51 million. During the same period in the previous year, the company posted $1.14 EPS. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. Equities analysts anticipate that Integer Holdings Co. will post 6.01 EPS for the current year.

Hedge Funds Weigh In On Integer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mather Group LLC. grew its holdings in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Integer during the 4th quarter valued at $27,000. Opal Wealth Advisors LLC purchased a new position in shares of Integer during the 1st quarter valued at $28,000. AdvisorNet Financial Inc purchased a new position in shares of Integer during the 1st quarter valued at $28,000. Finally, SVB Wealth LLC purchased a new position in shares of Integer during the 1st quarter valued at $35,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ITGR shares. KeyCorp reduced their target price on shares of Integer from $154.00 to $145.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Raymond James raised their target price on shares of Integer from $145.00 to $150.00 and gave the stock an “outperform” rating in a report on Friday, April 25th. Truist Financial set a $150.00 target price on shares of Integer and gave the stock a “buy” rating in a report on Friday, April 25th. Finally, Benchmark reduced their target price on shares of Integer from $150.00 to $140.00 and set a “buy” rating for the company in a report on Friday, April 25th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.